Cargando…

肺癌干性样细胞与耐药

Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung canc...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913289/
https://www.ncbi.nlm.nih.gov/pubmed/35224964
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02
_version_ 1784667403643256832
collection PubMed
description Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would like to present recent knowledges on LCSCs, including the origins where they come from, the molecular features to identify them, and key mechanisms for them to survive and develop resistance, in order to provide a better view for targeting them in future clinic.
format Online
Article
Text
id pubmed-8913289
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-89132892022-03-25 肺癌干性样细胞与耐药 Zhongguo Fei Ai Za Zhi 综述 Lung cancer remains the leading cause of cancer-related death world-wide. Therapy resistance and relapse are considered major reasons contributing to the poor survival rates of lung cancer. Accumulated evidences have demonstrated that a small subpopulation of stem-like cells existed within lung cancer tissues and cell lines, possessing the abilities of self-renewal, multipotent differentiation and unlimited proliferation. These lung cancer stem-like cells (LCSCs) can generate tumors with high effeciency in vivo, survive cytotoxic therapies, and eventually lead to therapy resistance and recurrence. In this review, we would like to present recent knowledges on LCSCs, including the origins where they come from, the molecular features to identify them, and key mechanisms for them to survive and develop resistance, in order to provide a better view for targeting them in future clinic. 中国肺癌杂志编辑部 2022-02-20 /pmc/articles/PMC8913289/ /pubmed/35224964 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
肺癌干性样细胞与耐药
title 肺癌干性样细胞与耐药
title_full 肺癌干性样细胞与耐药
title_fullStr 肺癌干性样细胞与耐药
title_full_unstemmed 肺癌干性样细胞与耐药
title_short 肺癌干性样细胞与耐药
title_sort 肺癌干性样细胞与耐药
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913289/
https://www.ncbi.nlm.nih.gov/pubmed/35224964
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.02
work_keys_str_mv AT fèiáigànxìngyàngxìbāoyǔnàiyào
AT fèiáigànxìngyàngxìbāoyǔnàiyào
AT fèiáigànxìngyàngxìbāoyǔnàiyào